Drug Discovery & Pharmaceuticals

RSS
Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Miniaturization in Medtech

Miniaturization in Medtech

Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis

Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis

How antibody-drug conjugates are redefining targeted cancer therapy

How antibody-drug conjugates are redefining targeted cancer therapy

New mechanism to enhance precision in cancer drug development

New mechanism to enhance precision in cancer drug development

Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit

Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit

Fujitsu and IBM Japan formalize collaboration in healthcare sector

Fujitsu and IBM Japan formalize collaboration in healthcare sector

Study identifies breakthrough drug combination for early-stage Peyronie’s

Study identifies breakthrough drug combination for early-stage Peyronie’s

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

Penn researchers develop ApexGO to enhance promising antibiotic candidates

Penn researchers develop ApexGO to enhance promising antibiotic candidates

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Bruker unveils new NMR products and workflow solutions at ENC 2026

Bruker unveils new NMR products and workflow solutions at ENC 2026

Cranberry juice may help stop antibiotic resistance in UTIs

Cranberry juice may help stop antibiotic resistance in UTIs

Organic lithium salts may affect many cellular level changes in Alzheimer's disease

Organic lithium salts may affect many cellular level changes in Alzheimer's disease

New inhibitor design provides a blueprint for effective malaria treatments

New inhibitor design provides a blueprint for effective malaria treatments

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

NIH awards $3.9 million grant to develop a non-opioid pain treatment

NIH awards $3.9 million grant to develop a non-opioid pain treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.